Brief: Valbiotis Presents Full Results Of Phase II/III REVERSE-IT Study

Valbiotis SA

11/09/2023 16:45

Sept 11 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS SA: VALBIOTIS PRESENTS THE FULL RESULTS OF THE
PHASE
II/III REVERSE-IT STUDY: IMPRESSIVE EFFICACY OF TOTUM•63 AGAINST
PREDIABETES AND THE EARLY STAGES OF TYPE 2 DIABETES
    * STUDY CONFIRMS TOTUM 63'S EXCELLENT SAFETY PROFILE AND A
COMPLIANCE EXCEEDING 97%
    * WE ALSO DEMONSTRATED A 40% REDUCTION IN NUMBER OF NEW
DIAGNOSES
OF TYPE 2 DIABETES AMONG PREDIABETICS
    * RESULTS OF MODE-OF-ACTION CLINICAL STUDY ON TOTUM•63
CONDUCTED
BY INAF IN QUEBEC CITY ARE EXPECTED IN SECOND HALF OF 2023
    * 40% RELATIVE REDUCTION IN NEW CASES OF TYPE 2 DIABETES AT
END OF
STUDY VERSUS PLACEBO
    * NEXT SCIENTIFIC STEPS WILL INCLUDE SUBMISSION OF CLINICAL
DATA
FROM REVERSE-IT STUDY TO INTERNATIONAL CONGRESSES AND
PUBLICATION IN INTERNATIONAL PEER-REVIEWED JOURNALS
    * SIGNIFICANTLY REDUCES LOW-GRADE INFLAMMATION (-13% OF
PATIENTS
ABOVE THRESHOLD)
    * SIGNIFICANTLY REDUCES FASTING BLOOD GLUCOSE, 2-HOUR BLOOD
GLUCOSE, GLYCATED HEMOGLOBIN, HOMA-IR INSULIN RESISTANCE SCORE

Source text for Eikon:  ID:nEQ8RdKHna 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))